AHA 2022｜日程早知道！9个LBS专场，9个FS专场，近80项研究结果即将揭晓

2022-11-08 21:31

11月5日-7日，2022年美国心脏协会科学年会（AHA 2022）将于芝加哥拉开帷幕，并同步举办线上会议。为期3天的会议设置9个Late-Breaking Science（LBS）专场，9个Featured Science（FS）专场，相继公布共计近80项研究结果。

届时，严道医声网将持续跟踪报道，并邀请专家进行解读，官网日程早知道，更多最新信息邀您持续关注。

声明：严道医声网致力于传播权威、前沿的学术信息，及时将领域时事、前沿学术内容传递至国内，各项内容资料版权均归AHA 2022所有，如有涉及版权等问题，请第一时间与我们联系。

Late-Breaking Science（LBS)

LBS 01：改变临床实践的重大事件

北京时间：11月5日10:30PM-11:30PM

1.Comparative Effectiveness of Torsemide versus Furosemide in Heart Failure: Primary Results of the TRANSFORM-HF Trial

1.TRANSFORM-HF试验主要结果：托拉塞米和呋塞米治疗心力衰竭的疗效比较

2.Chlorthalidone Compared to Hydrochlorothiazide for the Prevention of Cardiovascular Events in Patients With Hypertension

2.DCP研究：氯噻酮和氢氯噻嗪预防高血压患者心血管事件的比较

3.A Randomized Trial of Pemafibrate for Triglyceride Reduction in the Prevention of Cardiovascular Disease

3.PROMINENT试验：Pemafibrate降低甘油三酯对心血管疾病预防作用的随机试验

LBS 02：心力衰竭突破性治疗策略

北京时间：11月6日4:00AM-5:00AM

4.First-in-Human in vivo Crispr/Cas9 Editing of the Ttr Gene by Ntla-2001 in Patients With Transthyretin Amyloidosis With Cardiomyopathy

4.体内CRISPR/Cas9基因编辑疗法Ntla-2001用于甲状腺素蛋白淀粉样变心肌病的首个人体试验结果

5.A Patient-Risk Based Health System Intervention for Acute Heart Failure Care: The Comparison of Outcomes and Access to Care for Heart Failure (COACH) Trial

5.COACH试验：基于患者风险的健康系统干预在急性心力衰竭护理中作用

6.Early Results of the Patient-Reported Outcome Measurement in Heart Failure Clinic (PRO-HF) Trial

6.患者报告的心力衰竭临床结局测量（PRO-HF）试验的初步结果

7.IRONMAN: A Randomized Trial of Intravenous Ferric Derisomaltose in Heart Failure With Reduced Ejection Fraction

7.IRONMAN试验：静脉注射Ferric Derisomaltose治疗射血分数降低的心力衰竭患者的随机试验

LBS 03：介入和手术的高影响力试验

北京时间：11月6日10:00PM-11:00PM

8.Radial Artery Patency and Clinical Outcomes (RAPCO) Randomized Trials - The 15-Year Clinical Outcomes Comparing Radial Artery With Right Internal Thoracic Artery or With Saphenous Vein Grafting

8.桡动脉通畅性和临床结局（RAPCO）试验：桡动脉与右胸内动脉/隐静脉移植的15年临床疗效比较

9.Steroids to Reduce Systemic Inflammation After Infant Heart Surgery: The Stress Trial

9.STRESS试验：类固醇可减少婴儿心脏手术后的全身炎症

10.The Impact of Chinese Herbal Medicine, Tongxinluo in Patients With Acute Myocardial Infarction— Results From the CTS-AMI Trial

10.CTS-AMI试验结果：中药通心络对急性心肌梗死患者的影响

11.Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Primary Results From the Multicenter, Randomized ECMO-CS Trial

11.多中心随机ECMO-CS试验的主要结果：体外膜肺氧合治疗心源性休克

LBS 04：慢性高血压管理的正念干预

北京时间：11月7日5:30AM-6:30AM

12.Effectiveness of a Village Doctor-Led Multifaceted Implementation Strategy on Cardiovascular Disease Among Patients With Hypertension: A Cluster Randomized Trial

12.乡村医生主导的心血管疾病防治多方位实施策略对高血压患者心血管疾病防治的有效性：集群随机CRHCP试验

13.Reducing Inequities in Care of Hypertension: Lifestyle Improvement for Everyone): Blood Pressure and Patient-Reported Outcomes (the Rich Life Project)

13.Rich Life Project研究：减少高血压护理中的不平等，改善每个人的生活方式：血压和患者报告的结果

14.The Effect of Adapted Mindfulness Training in Participants With Elevated Office Blood Pressure: The Mindfulness-Based Blood Pressure Reduction (MB-BP) Randomized Clinical Trial

14.正念训练对诊室血压升高患者的影响：MB-BP随机临床试验

15.Efficacy and Safety of a Quadruple Ultra-Low-Dose Treatment for Hypertension (QUARTET USA): A Randomized Controlled Trial

15.四联超低剂量治疗高血压的疗效和安全性：QUARTET USA随机对照试验

LBS 05：改变心血管和肾脏疾病的预防方式

北京时间：11月7日7:00AM-8:00AM

16.Randomized Trial for Evaluating Secondary Prevention Efficacy of Combination Therapy -Statin and Eicosapentaenoic Acid

16.RESPECT-EPA试验：评价他汀类药物和二十碳五烯酸联合治疗用于心血管疾病二级预防效果的随机试验

17.Reduction of Lipoprotein(a) With Small Interfering RNA: The Results of the Ocean(a)-DOSE Trial

17.Ocean(a)-DOSE试验结果：小干扰RNA降低脂蛋白(a)水平

18.Empagliflozin and Cardiovascular Outcomes in Patients With Chronic Kidney Disease: The EMPA-KIDNEY Trial

18.EMPA-KIDNEY试验：恩格列净对慢性肾脏疾病患者心血管结局的影响

19.Effect of Low-Dose Statin Compared With Placebo and Six Dietary Supplements on Lipid and Inflammatory Biomarkers: The SPORT Randomized Clinical Trial

19.SPORT随机临床试验：与安慰剂和6种膳食补充剂相比，低剂量他汀对血脂和炎症生物标志物的影响

LBS 06：ACS和血运重建患者的治疗策略

北京时间：11月7日7:00AM-8:00AM

20.Bivalirudin With a Post-Pci High-Dose Infusion versus Heparin Monotherapy During Primary Pci in Stemi: The Randomized Bright-4 Trial

20.BRIGHT-4随机试验：STEMI患者直接PCI术后大剂量输注比伐卢定与肝素单药治疗的比较

21.Efficacy and Safety of Indobufen versus Aspirin After Coronary Drug-Eluting Stent Implantation: A Randomized, Open-Label, Non-Inferiority Trial

21.随机、开放标签、非劣效性OPTION试验：冠状动脉药物洗脱支架置入后吲哚布芬 vs. 阿司匹林的疗效和安全性

22.Comparison of a Precision Care Strategy With Usual Testing to Guide Management of Stable Patients With Suspected Coronary Artery Disease: The Precise Randomized Trial

22.PRECISE随机试验：在病情稳定的疑似冠状动脉疾病患者中，精准管理策略和常规管理策略的比较

23.ISCHEMIA-EXTENDed Follow-Up Interim Report

23.ISCHEMIA-EXTENDed试验后续中期报告

LBS 07：外周血管疾病的血管介入和药物治疗

北京时间：11月7日10:00PM-11:00PM

24.Best Endovascular versus Best Surgical Therapy for Patients With Chronic Limb Threatening Ischemia (BEST-CLI) Trial: Clinical Results

24.BEST-CLI临床结果 (Clinical) ：慢性肢体威胁性缺血患者的最佳血管内治疗与最佳手术治疗

25.Best Endovascular versus Best Surgical Therapy for Patients With Chronic Limb Threatening Ischemia (BEST-CLI) Trial: Quality of Life Analyses

25.BEST-CLI生活质量分析 (QOL) ：慢性肢体威胁性缺血患者的最佳血管内治疗与最佳手术治疗

26.Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Covid-19: Primary Results of the PREVENT-HD Randomized Clinical Trial

26.PREVENT-HD随机临床试验的主要结果：在COVID-19门诊患者中，利伐沙班可降低主要静脉和动脉血栓事件、住院和死亡风险

27.A Multicenter Clustered Randomized Trial of a Universal Electronic Health Record-Based Venous Thromboembolism Risk Assessment Model as Integrated Clinical Decision Support for Prevention of Thromboembolism in Hospitalized Medically-Ill Patients

27.IMPROVE多中心集群随机试验，基于通用电子健康记录的静脉血栓栓塞风险评估模型用于住院内科患者血栓栓塞预防的综合临床决策支持

LBS 08：房性和室上性心律失常的治疗

北京时间：11月8日1:00AM-2:00AM

28.The Impact of “First-Line” Rhythm Therapy on Atrial Fibrillation Progression: The Progressive-AF Trial

28.PROGRESSIVE-AF试验：“一线”节律治疗对房颤进展的影响

29.Self-Administered Etripamil for Termination of Spontaneous Paroxysmal Supraventricular Tachycardia: Primary Analysis From the Rapid Study

29.RAPID研究初步分析结果：Etripamil自行给药终止自发性阵发性室上性心动过速

30.Efficacy and Safety of Botulinum Toxin Type A for the Prevention of Postoperative Atrial Fibrillation in Cardiac Surgery Patients: Results From the Phase 2 Nova Study

30.NOVA 2期研究结果：A型肉毒毒素预防心脏手术患者术后房颤的疗效和安全性

31.Clinical Trial to Evaluate an Atrial Fibrillation Stroke Prevention Shared Decision-Making Pathway

31.ENHANCE-AF试验：评价房颤卒中预防共享决策路径的临床试验

LBS 09：难治性高血压的管理

北京时间：11月8日5:00AM-6:00AM

32.Top-Line Results of The First-in-Class Aminopeptidase-A Inhibitor Firibastat in Treatment-Resistant Hypertension (FRESH) Study

32.FRESH研究Top-Line结果：First-in-Class药物氨基肽酶A抑制剂Firibastat治疗难治性高血压

33.Sustained Blood Pressure Lowering Effect With the Dual Endothelin Receptor Antagonist Aprocitentan in Resistant Hypertension: Results From a Randomized, Controlled Study Including a Withdrawal Phase

33.PRECISION随机对照研究（包括退出期）：双内皮素受体拮抗剂Aprocitentan对难治性高血压的持续降压作用

34.Results From a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Baxdrostat in Patients With Treatment-Resistant Hypertension

34.2期、随机、双盲、安慰剂对照BrigHTN试验：评估Baxdrostat在难治性高血压患者中疗效和安全性

35. Effect of Radiofrequency Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 6-Month Primary Results From the SPYRAL HTN-ON Med Expansion Randomized Trial

35.SPYRAL HTN-ON扩展随机试验的6个月主要结果：在接受降压药物治疗的患者中，射频消融去肾交感神经术对血压的影响

Featured Science（FS）

FS 01：心力衰竭试验深度解读和新视角

北京时间：11月6日10:00PM-11:00PM

36.The Effect of Percutaneous Revascularization on Arrhythmic Risk in Ischemic Left Ventricular Dysfunction

36.REVIVED-BCIS2试验：经皮血运重建术对缺血性左心室功能不全患者心律失常风险的影响

37.Natriuretic Response With Acetazolamide in Acute Heart Failure With Volume Overload: Analysis From the ADVOR Trial

37.ADVOR试验分析结果：乙酰唑胺治疗急性心力衰竭伴容量超负荷患者的利尿钠反应

38.Decongestion With Acetazolamide in Acute Decompensated Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction: A Pre-Specified Analysis From the Advor Trial

38.ADVOR试验预先指定分析（decongestion）：根据左心室射血分数范围使用乙酰唑胺缓解急性失代偿性心力衰竭患者的充血症状

39.Empagliflozin and Cardiac Remodeling in People Without Diabetes: Primary Results of EMPA-HEART 2 CardioLink-7 Randomized Placebo-Controlled Trial

39.EMPA-HEART 2 CardioLink-7随机安慰剂对照试验的主要结果：无糖尿病患者服用恩格列净对心脏重塑的影响

40.First and Repeat Episodes of Worsening Heart Failure in Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction: An Analysis of Deliver

40.DELIVER试验分析：在射血分数轻度降低和保留的心力衰竭患者中，心衰恶化的首次发生和复发情况

FS 02：心脏外科治疗新见解

北京时间：11月6日11:30PM-00:30AM

41.Myosin Inhibition in Patients With Obstructive HCM Referred for Septal Reduction Therapy: 32-Week Active Blinded Crossover Results From Valor-HCM Trial

41.VALOR-HCM试验的32周主动盲法交叉结果：肌球蛋白抑制剂用于梗阻性肥厚型心肌病患者的室间隔减容治疗

42.Electrocardiographic Changes After Cardiac Surgery and 30-Day Mortality

42.VISION Cardiac Surgery试验：心脏手术后心电图变化和30天死亡率

43.Interim Results of a Phase 2 Study With RBT-1 Evaluating Postoperative Course in Patients Undergoing Elective CABG/Valve Surgery on Cardiopulmonary Bypass

43.2期START研究的中期结果：使用RBT-1评估接受体外循环择期CABG/瓣膜手术患者术后病程

44.Results From the Clinical Implementation of Partial Oral Treatment of Patients With Infectious Endocarditis; A Nationwide Study. Time for Poetry?

44.一项全国性研究：评估感染性心内膜炎患者部分口服治疗的临床结果

FS 03：心律失常管理

北京时间：11月7日7:00AM-8:00AM

45.Feasibility and Safety of Intravenous Sotalol Administered as a Loading Dose to Initiate Oral Sotalol Therapy in Adult Patients With Atrial Fibrillation

45.DASH-AF研究：成人房颤患者启动口服索他洛尔治疗时，静脉注射负荷剂量索他洛尔的可行性和安全性

46.Subcutaneous Implantable Cardioverter-Defibrillator System Post Approval Study: Primary Results

46.S-ICD PAS研究主要结果：皮下植入式心脏复律除颤器系统上市后研究

47.Apixaban or Vitamin K Antagonists for Stroke Prevention in Patients With Atrial Fibrillation on Hemodialysis: Results of the Randomized Axadia-AFNET 8 Trial

47.AXADIA-AFNET 8随机试验结果：阿哌沙班或维生素K拮抗剂用于血液透析房颤患者的卒中预防

48. Association of Genetic Risk and Outcomes in Patients With Early Rhythm Control Therapy in Atrial Fibrillation: Results From the East-afnet4 Study

48.EAST-AFNET 4研究结果：房颤早期节律控制治疗患者的遗传风险与预后关系

FS 04：心力衰竭的新兴科学

北京时间：11月7日10:00PM-11:00PM

49. Safety and Efficacy of Non-Ischemic Hypothermic Machine Perfusion (NIHP) in Human Heart Transplantation With an Ischemic Time of 6-8 Hours

49.在缺血时间为6-8小时的心脏移植中，非缺血性低温机器灌注（NIHP）的安全性和有效性

50.A Randomized, Multicenter, Placebo-Controlled Trial of the Beta3 Adrenergic Agonist, Mirabegron on Left Ventricular Mass and Diastolic Function in Patients With Structural Heart Disease, the Beta3lvh Trial

50.一项随机、多中心、安慰剂对照BETA3LVH试验：β肾上腺素能激动剂米拉贝隆对结构性心脏病患者左心室质量和舒张功能的影响

51.The Prelieve Trial: Final 1-Year Outcomes of the Prospective Atrial Flow Regulator Study in Heart Failure Patients and Responder Analysis

51.PRELIEVE试验：前瞻性心力衰竭患者心房流量调节器研究的最终1年结果和应答分析

52.Exercise for the Prevention of Anthracycline-Induced Functional Disability and Cardiac Dysfunction: The Breast Cancer Exercise Intervention (BREXIT) Study

52.乳腺癌运动干预（BREXIT）研究：运动对蒽环类药物引起的功能障碍和心脏功能障碍的预防效果

53. Dissemination of a Decision Support Tool for Left Ventricular Assist Device: How a Majority of United States Programs Implemented I-DECIDE-LVAD into Standard Patient Evaluations

53.左心室辅助装置决策支持工具的推广：美国多数项目如何将I-DECIDE-LVAD应用到标准患者评估中

54.STRONG-HF: Successful Post-Discharge Management of Heart Failure

54.STRONG-HF研究：心力衰竭成功出院

FS 05：COVID-19中不断发展的科学

北京时间：11月7日10:00PM-11:00PM

55.Anti-c5a Vilobelimab Reduces All-Cause Mortality in Critically Ill Covid-19 Patients and in Those With Comorbid Hypertension: A Phase 3 Randomized Double-Blind, Placebo-Controlled Study

55.3期随机双盲、安慰剂对照PANAMO研究：抗c5a Vilobelimab可降低重症COVID-19患者和合并高血压患者的全因死亡率

56. A Randomized Trial of Lipid Metabolism Modulation With Fenofibrate for Acute Coronavirus Disease 2019

56.FERMIN试验：非诺贝特调节脂质代谢治疗COVID-19的随机试验

57.Impact of Coronavirus Disease-2019 on Participants in Deliver

57.DELIVER研究：COVID-19对受试者的影响

58.Rare Coding Variants in Cardiomyopathy-Associated Genes Predispose to Severe Covid-19 and Cardiac Injury

58.COVID-CARDOGEN研究：心肌病相关基因中的罕见编码变异易导致严重的COVID-19和心脏损伤

59.Prevalence of Myocarditis Among Patients Hospitalized With Laboratory-Confirmed SARS-CoV-2 Infection―14 US States, March 2020-May 2022

59.COVID-NET研究：2020年3月至2022年5月，美国14个州实验室确诊的SARS-CoV-2感染住院患者的心肌炎患病率

FS 06：PCI/ACS后的优化管理

北京时间：11月7日11:30PM-00:30AM

60.Long-Term Outcomes of an Invasive versus Conservative Strategy in Stabilised Patients Aged 80 Years or Older With Non-ST-Elevation Acute Coronary Syndrome, After Eighty Study: A Randomised Controlled Trial

60.一项随机对照试验（After Eighty）：年龄≥80岁非ST段抬高型急性冠脉综合征稳定型患者接受侵入性策略与保守策略的长期结果比较

61.Long Term Follow-Up of Aspirin vs. Clopidogrel Monotherapy in the Chronic Maintenance Period After Percutaneous Coronary Intervention: The Host-Exam Extended Study

61.HOST-EXAM扩展研究：在经皮冠状动脉介入治疗后的长期维持治疗中阿司匹林与氯吡格雷单药治疗的长期随访结果

62. Impact of Ticagrelor With or Without Aspirin on Total and Recurrent Bleeding and Ischemic Events After PCI: Results From the Twilight - Recurrent Events Sub-Study

62.TWILIGHT复发事件亚组研究结果：替格瑞洛联合或不联合阿司匹林对PCI后总出血和复发性出血及缺血事件的影响

63. Effect of Semaglutide on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes: Final Results of the Stop Study

63.STOP研究最终结果：Semaglutide对2型糖尿病患者冠状动脉粥样硬化进展的影响

FS 07：重新审视改变实践的心力衰竭试验

北京时间：11月8日1:00AM-2:00AM

64.The Effects of Dapagliflozin on Symptoms, Function and Quality of Life in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: Results From the DELIVER Trial

64.DELIVER研究结果：达格列净对射血分数轻度降低或保留的心力衰竭患者症状、功能和生活质量的影响

65.Baseline Characteristics, Outcomes, and Treatment Response to Dapagliflozin in Patients Treated With an MRA or ARNI in DELIVER

65.在DELIVER研究中接受MRA或ARNI治疗患者的基线特征、结局和达格列净治疗反应

66.Sex Differences in Characteristics, Outcomes and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure

66.DAPA-HF和DELIVER研究分析：心力衰竭患者临床特征的性别差异、预后和全射血分数范围内达格列净治疗反应

67.Differences in Clinical Characteristics, Outcomes, and Treatment Response to Dapagliflozin Across the Range of Ejection Fraction in Black and White Patients With Heart Failure: A Pooled Analysis of DAPA-HF and Deliver

67.DAPA-HF和DELIVER研究的汇总分析：黑人和白人心力衰竭患者的临床特征、预后和全射血分数范围内达格列净治疗反应差异

68.Comparison of Clinical Outcomes and Efficacy of Empagliflozin in Black vs White Patients With Heart Failure: A Pooled Analysis From the EMPEROR Program

68.EMPEROR项目的汇总分析：恩格列净在黑人和白人心力衰竭患者中的临床结果和疗效比较

69.Long Term Survival After Cardiac Resynchronization in Ambulatory Heart Failure

69.RAFT研究：门诊心力衰竭患者心脏再同步化治疗后的长期存活率

FS 08：改善心血管疾病预防的数字创新

北京时间：11月8日1:00AM-2:00AM

70.Randomized, Controlled Trial of Digital Nutritional Cognitive Behavioral Therapy in Patients With Type 2 Diabetes Mellitus: Primary Outcomes of the BT-001 Pivotal Trial at 180 Days

70.BT-001 PIVOTAL试验180天的主要结果：数字营养认知行为疗法在2型糖尿病患者应用的随机对照试验

71.A Randomized Controlled Trial of a Remotely Delivered Mobile Health Intervention to Augment Cardiac Rehabilitation: The Virtual AppLication-Supported ENvironment To INcrease Exercise: The VALENTINE Study

71.虚拟应用程序对增强练习的环境支持（VALENTINE研究）：远程移动健康干预用于增强心脏康复的随机对照试验

72.Smartphone-Based Cardiovascular Risk Reduction in Breast Cancer Patients: A Randomized Controlled Trial

72.随机对照SMART-BREAST试验：智能手机对乳腺癌患者心血管风险降低的影响

73.A PRagmatic Trial Of Messaging to Providers About Treatment of HyperLIPIDemia

73.PROMPT-LIPID研究：关于高脂血症治疗信息传递的实用试验

74.Incidental Coronary Artery Calcium: Opportunistic Screening of Prior Non-Gated Chest CTs to Improve Statin Rates - (Accepted, Not Confirmed)

74.NOTIFY-1研究：偶发性冠状动脉钙化患者早期非门控胸部CTs的机会性筛查可提高他汀类药物的使用率

FS 09：降脂治疗的现在和未来

北京时间：11月8日5:00AM-6:00AM

75.ARO-ANG3, an Investigational RNAi Therapeutic, Decreases Serum Angiopoietin-Like Protein 3, Triglycerides, and Cholesterol in Patients With Mixed Dyslipidemia

75.ARCHES-2研究：ARO-ANG3是一种实验性RNAi治疗药物，可降低混合性血脂异常患者的血清血管生成素样蛋白3、甘油三酯和胆固醇水平

76.ARO-APOC3, an Investigational RNAi Therapeutic, Decreases Serum Apolipoprotein C3, Triglyceride, and Non-HDL-C Concentrations While Increasing HDL-C in Patients With Severe Hypertriglyceridemia

76.ARCHES-2研究：ARO-ANG3是一种实验性RNAi治疗药物，可降低严重高甘油三酯血症患者的血清载脂蛋白C3、甘油三酯和non-HDL-C水平，同时升高HDL-C水平

77.Long-Term Efficacy of Very Low LDL-Cholesterol Levels With the PCSK9 Inhibitor Evolocumab: Analysis of the FOURIER and FOURIER-OLE Studies (FOURIER-OLE)

77.PCSK9抑制剂依洛尤单抗治疗极低LDL-C水平的长期疗效：FOURIER和FOURIER-OLE研究（FOURIER-OLE）

78.Efficacy and Safety of Twice-Yearly Subcutaneous Inclisiran in Patients With High Cardiovascular Risk and Elevated Low-Density Lipoprotein Cholesterol up to 4 Years-The Orion-3 Trial

78.ORION-3试验的4年结果：每年两次皮下注射Inclisiran在高心血管风险和LDL-C水平升高患者中的疗效和安全性

79.Individual Participant Data Meta-Analysis of New-Onset and Worsening Diabetes Mellitus in Large-Scale Randomized Double-Blind Trials of Statin Therapy

79.在他汀类药物治疗的大规模随机双盲试验中，新发和恶化糖尿病的个体参与者数据的荟萃分析

更多信息，请持续关注！

阅读数: 867